Drug Profile


Alternative Names: AST-OPC1; GRNOPC 1; hESC-derived oligodendrocyte progenitor cells (OPC) - Geron/University of California; Oligodendrocyte progenitor cells - Asterias Biotherapeutics; OPC-1

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Spinal cord injuries
  • Preclinical Canavan disease; Multiple sclerosis; Stroke
  • Discontinued Alzheimer's disease

Most Recent Events

  • 03 Aug 2017 Asterias Biotherapeutics expects to complete enrolment in the phase I/IIa SCiSTAR trial for Spinal cord injuries in USA in late 2017
  • 10 Jul 2017 The US FDA approves amendment to enrol C4 patients in phase I/II SCiStar trial in Spinal cord injuries
  • 13 Jun 2017 Updated efficacy data from the SCiSTAR phase I/IIa trial in Spinal cord injuries released by Asterias Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top